obesity
OBESITY
Obesity is having an excessive amount of body fat that may impair health.
The primary cause is an energy imbalance between calories consumed and expended.
Treatment goals include addressing the principal cause of weight gain and focusing management on both weight loss and patient-centered health outcomes.
A multidisciplinary approach, that is a combination of dietary change, physical activity and behavioral modification, is recommended.

Obesity Drug Information

Drug Information

Indication: Adjunctive therapy to diet in patients w/ obesity & BMI ≥30, who have not responded to an appropriate w...

Indication: Short-term adjunct in the management of obesity in a medically monitored comprehensive regimen of wt reduction...

Indication: Iin conjunction w/ a mildly hypocaloric diet for obese (BMI ≥30 kg/m2) & overwt (BMI ≥28 ...

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, Yesterday
Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
Roshini Claire Anthony, Yesterday

In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.